Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir
- 18 December 2007
- journal article
- Published by Wiley in HIV Medicine
- Vol. 9 (2), 89-95
- https://doi.org/10.1111/j.1468-1293.2007.00525.x
Abstract
The aim of the study was to determine the factors that may contribute to decreases in bone mineral density (BMD) in patients with AIDS. This was a prospective, non-randomized study. Dual X-ray absorptiometry (DXA) was used to determine the BMD of the lumbar spine, femoral neck and distal radius in treatment-naïve HIV-infected male patients with AIDS before and after 1 year of treatment with zidovudine (ZDV)/lamivudine (3TC) plus abacavir (ABC) or lopinavir/ritonavir (LPV/r). Basal DXA was performed in 50 patients with CD4 counts <200 cells/microL and/or any AIDS-defining condition. Thirty-two patients completed 1 year with full adherence (17 on ABC and 15 on LPV/r) and a second DXA was then performed. At baseline, 19% had osteopenia at the lumbar spine and 19% at the femoral neck. Low body weight was related to low BMD. After 48 weeks, BMD loss was significant at the three locations. The percentage of BMD loss at the femoral neck tended to be greater in the lopinavir group (5.3 vs. 3.2%, P=0.058). The differences became significant at the lumbar spine (5.7 vs. 2.7%, P=0.044). In the multivariate analysis, the treatment with LPV/r remained associated with bone loss at the lumbar spine. Osteopenia is frequent in treatment-naïve HIV-infected men with AIDS. Bone loss is higher with LPV/r-based regimens compared with triple nucleoside reverse transcriptase inhibitors.Keywords
This publication has 24 references indexed in Scilit:
- Modulation of Osteoclastogenesis Induced by Nucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2006
- Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti‐Retroviral Therapy for AIDSAnnals of the New York Academy of Sciences, 2006
- Bone Disease and HIV InfectionClinical Infectious Diseases, 2006
- CD4+ Cell Count, Viral Load, and Highly Active Antiretroviral Therapy Use Are Independent Predictors of Body Composition Alterations in HIV-Infected Adults: A Longitudinal StudyClinical Infectious Diseases, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialPublished by American Medical Association (AMA) ,2004
- Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapyAIDS, 2003
- Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapyAIDS, 2003
- Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsClinical Infectious Diseases, 2003
- Prospective, Intensive Study of Metabolic Changes Associated with 48 Weeks of Amprenavir‐Based Antiretroviral TherapyClinical Infectious Diseases, 2002
- Select HIV Protease Inhibitors Alter Bone and Fat Metabolism ex VivoPublished by Elsevier BV ,2002